Your browser doesn't support javascript.
Protective CD8+ T Cell Response Induced by Modified Vaccinia Virus Ankara Delivering Ebola Virus Nucleoprotein.
Kupke, Alexandra; Volz, Asisa; Dietzel, Erik; Freudenstein, Astrid; Schmidt, Jörg; Shams-Eldin, Hosam; Jany, Sylvia; Sauerhering, Lucie; Krähling, Verena; Gellhorn Serra, Michelle; Herden, Christiane; Eickmann, Markus; Becker, Stephan; Sutter, Gerd.
  • Kupke A; Institute of Virology, Philipps University Marburg, 35043 Marburg, Germany.
  • Volz A; German Center for Infection Research, Partner Site Giessen-Marburg-Langen, 35043 Marburg, Germany.
  • Dietzel E; Institute of Virology, University of Veterinary Medicine Hannover, 30559 Hannover, Germany.
  • Freudenstein A; German Center for Infection Research, Partner Site Munich, 80539 Munich, Germany.
  • Schmidt J; Institute of Virology, Philipps University Marburg, 35043 Marburg, Germany.
  • Shams-Eldin H; German Center for Infection Research, Partner Site Giessen-Marburg-Langen, 35043 Marburg, Germany.
  • Jany S; Division of Virology, Institute for Infectious Diseases and Zoonoses, LMU Munich, 80539 Munich, Germany.
  • Sauerhering L; Institute of Virology, Philipps University Marburg, 35043 Marburg, Germany.
  • Krähling V; German Center for Infection Research, Partner Site Giessen-Marburg-Langen, 35043 Marburg, Germany.
  • Gellhorn Serra M; Institute of Virology, Philipps University Marburg, 35043 Marburg, Germany.
  • Herden C; Division of Virology, Institute for Infectious Diseases and Zoonoses, LMU Munich, 80539 Munich, Germany.
  • Eickmann M; Institute of Virology, Philipps University Marburg, 35043 Marburg, Germany.
  • Becker S; German Center for Infection Research, Partner Site Giessen-Marburg-Langen, 35043 Marburg, Germany.
  • Sutter G; Institute of Virology, Philipps University Marburg, 35043 Marburg, Germany.
Vaccines (Basel) ; 10(4)2022 Mar 29.
Article in English | MEDLINE | ID: covidwho-1810347
ABSTRACT
The urgent need for vaccines against Ebola virus (EBOV) was underscored by the large outbreak in West Africa (2014-2016). Since then, several promising vaccine candidates have been tested in pre-clinical and clinical studies. As a result, two vaccines were approved for human use in 2019/2020, of which one includes a heterologous adenovirus/Modified Vaccinia virus Ankara (MVA) prime-boost regimen. Here, we tested new vaccine candidates based on the recombinant MVA vector, encoding the EBOV nucleoprotein (MVA-EBOV-NP) or glycoprotein (MVA-EBOV-GP) for their efficacy after homologous prime-boost immunization in mice. Our aim was to investigate the role of each antigen in terms of efficacy and correlates of protection. Sera of mice vaccinated with MVA-EBOV-GP were virus-neutralizing and MVA-EBOV-NP immunization readily elicited interferon-γ-producing NP-specific CD8+ T cells. While mock-vaccinated mice succumbed to EBOV infection, all vaccinated mice survived and showed drastically decreased viral loads in sera and organs. In addition, MVA-EBOV-NP vaccinated mice became susceptible to lethal EBOV infection after depletion of CD8+ T cells prior to challenge. This study highlights the potential of MVA-based vaccines to elicit humoral immune responses as well as a strong and protective CD8+ T cell response and contributes to understanding the possible underlying mechanisms.
Keywords

Full text: Available Collection: International databases Database: MEDLINE Topics: Vaccines Language: English Year: 2022 Document Type: Article Affiliation country: Vaccines10040533

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Topics: Vaccines Language: English Year: 2022 Document Type: Article Affiliation country: Vaccines10040533